Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference
Daix (France), New York City (New York, United States), August 11, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that Jason Campagna, MD, PhD, President of R&D and Chief Medical Officer, and David Nikodem, PhD, Vice President of US Operations will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference. The conference is being held from August 12-14, 2025, at the InterContinental Hotel in Boston, Massachusetts.
During the fireside chat, Drs. Campagna and Nikodem will highlight recent corporate updates, progress on lanifibranor and the Phase III NATiV3 trial in MASH and discuss the Company’s broader R&D strategy and outlook.
Related Questions
What is the current cash runway and will additional financing be needed to support the Phase III trial?
How will the upcoming fireside chat influence investor sentiment and volume at the conference?
What are the potential regulatory hurdles for lanifibranor in the U.S. and Europe?
How does Inventiva’s R&D pipeline beyond lanifibranor affect its long‑term valuation?
What is the current share ownership structure and any recent insider transactions?
How might the conference presentation affect analyst estimates and price targets?
What are the expected timelines and milestones for the Phase III NATiV3 trial, and how might they affect the stock price?
How does lanifibranor’s efficacy and safety data compare to other MASH treatments in development?
What is the potential market size and revenue opportunity for lanifibranor if the trial is successful?
What are the competitive dynamics in the MASH therapeutic space and who are the key competitors?